sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_13413> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_13413> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00994> ;
    a rdf:Statement ;
    rdfs:label "to reduce the development of drug resistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy suppression of intestinal bacteria neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel e g preoperative preparation of the bowel it is given concomitantly with erythromycin enteric coated base see dosage and administration hepatic coma portal systemic encephalopathy neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia forming bacteria in the intestinal tract the subsequent reduction in blood ammonia has resulted in neurologic improvement" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB00994> bl:category bl:Drug .
}